This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rubinstein, D. B. Articles by Guillaume, T. Search for Related Content PubMed PubMed Citation Articles by Rubinstein, D. B. Articles by Guillaume, T.

Overexpression of DNA-binding Protein B Gene Product in Breast Cancer as Detected by in Vitro-generated Combinatorial Human Immunoglobulin Libraries¹

Section of Hematology/Oncology [D. B. R., A. S.] and Cancer Research Center [M. B.], Boston University School of Medicine, Boston, Massachusetts 02118; Department of Surgical Pathology, Division of Cytopathology, University of Texas Southwestern Medical Center, Dallas, Texas 60620 [R. A.]; and Laboratory of Experimental Oncology, University of Louvain, 1200 Brussels, Belgium [T. G.]

Molecules differentially expressed or overexpressed by malignant cells can serve in detecting and tracking of tumor. Additionally, they potentially can be applied in histologic-specific antitumor therapy. Few breast cancer-associated candidate molecules have been identified. Here we describe the use of combinatorial immunoglobulin [antigen-binding fragment of immunoglobulin molecule (Fab) fragment] phage libraries generated from patients with breast carcinoma to identify cancer-associated gene expression. The libraries were enriched for tumor-binding Fab by 3 logs and yielded a group of antibodies against DNA-binding protein B (DbpB), a 35-kDa thrombin-inducible nuclear factor and member of the Y-box family of proteins, which are known to act both negatively in selective gene suppression and positively as promoters of gene transcription. Sequencing of the anti-DbpB showed a degree of heterogeneity and bp substitutions suggesting that the Fabs selected from the combinatorial library represented a varied anti-DbpB immune response and did not simply arise from in vitro amplification by PCR of a single or limited numbers of immunoglobulin genes. Sequencing of the DbpB molecule expressed in malignant breast cancer showed no evidence of tumor-specific mutations. Evaluation of levels of DbpB gene product expression however showed the molecule to be constitutively expressed in normal nonmalignant breast tissues but to have consistently differentially higher expression in breast cancer. Immunohistological staining revealed DbpB to be present both intracellularly and on the cell surface, which suggests it may be a means whereby malignant cells repair and replicate DNA in a selectively advantageous manner as compared with nonmalignant cells. DbpB expression in breast cancer may advance the basic understanding of the role of Y-box binding proteins as regulatory agents, and in defining malignant cell phenotypes. In addition, DbpB and the antibodies generated against it may have direct application in tumor detection and in molecule-targeted immunotherapy.

This article has been cited by other articles:

				J. Wu, C. Lee, D. Yokom, H. Jiang, M. C.U. Cheang, E. Yorida, D. Turbin, I. M. Berquin, P. R. Mertens, T. Iftner, et al. Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2. Cancer Res., May 1, 2006; 66(9): 4872 - 4879. [Abstract] [Full Text] [PDF]

				I. Gaudreault, D. Guay, and M. Lebel YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins Nucleic Acids Res., January 12, 2004; 32(1): 316 - 327. [Abstract] [Full Text] [PDF]